Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that are likely to benefit from the overseas AI healthcare performance, specifically mentioning companies like RunDa Medical and YiMaiTong as having strong potential for AI-driven revenue growth [5][10]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring companies such as RunDa Medical, YiMaiTong, and others that are expected to achieve rapid AI performance growth [10]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top five performing stocks during this period included Changshan Pharmaceutical (up 23.59%), Xiangxue Pharmaceutical (up 19.64%), and others [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei for AI applications across various healthcare settings, providing digital solutions to over 80 hospitals by the end of 2024 [12][13]. - YiMaiTong, a leading online professional physician platform, has seen its registered physician count grow from 228,000 in 2018 to 867,000 in 2024, with a compound annual growth rate (CAGR) of 24.9% [17][20]. The company’s revenue increased from 83.46 million yuan to 558.46 million yuan from 2018 to 2024, reflecting a CAGR of 37.3% [20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and others, indicating a focus on innovative drugs and companies with emerging performance [5]. 5. Market Valuation and Trading Volume - As of May 9, 2025, the overall valuation of the Shenwan Pharmaceutical sector was 32.3, with a slight increase from the previous week [38]. The total trading volume for the sector reached 287.2 billion yuan, accounting for 5.3% of the total A-share trading volume [40].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [2]. Core Insights - The report highlights a significant rebound in the stock prices of leading US healthcare AI companies, with Tempus and Grail both experiencing a 65% increase over the past month. This sector is noted for its rapid implementation and growing investor interest [8][10]. - It suggests focusing on domestic companies that can mirror the growth of these US AI leaders, particularly those like RunDa Medical and YiMaiTong, which are positioned to leverage AI for substantial performance gains [10][12]. Summary by Sections 1. Focus on US AI Leaders and Domestic Opportunities - The report emphasizes the recent stock price rebounds of US healthcare AI leaders, with notable increases of 65% for Tempus and Grail, and suggests that AI in healthcare is one of the fastest-growing fields [8]. - It recommends monitoring domestic companies such as RunDa Medical and YiMaiTong for potential investment opportunities as they implement AI solutions [10][12]. 2. Weekly Market Review and Hotspot Tracking (May 6 - May 9, 2025) - The report notes that the Shenwan Pharmaceutical and Biotechnology Index rose by 1.01% during the week, underperforming the CSI 300 Index by 1.0%. Year-to-date, the index has increased by 1.19%, outperforming the CSI 300 by 3.44% [32]. - The top-performing stocks during this period included Changshan Pharmaceutical (up 23.59%) and Xiangxue Pharmaceutical (up 19.64%) [44]. 3. Company Highlights - RunDa Medical has established deep collaborations with Huawei to implement AI solutions across over 80 hospitals, enhancing its digital healthcare offerings [12][13]. - YiMaiTong, a leading online professional physician platform in China, has seen its registered physician count grow to over 4 million, with a compound annual growth rate (CAGR) of 24.9% in paid clicks from 2018 to 2024 [17][20]. 4. Monthly Investment Portfolio - The report lists a monthly investment portfolio that includes companies such as Kangfang Biotech, Zai Lab, and Titan Technologies, indicating a focus on firms with strong fundamentals and growth potential [5].

不仅仅是创新药，低迷数年的院外医药赛道也正重新成为公募基金卡位时代的新机会。 券商中国记者注意到，随着关税因素促使内需消费成为公募基金二季度挖掘股票的核心考量，叠加院外医药市 场复苏，今年四月底开始，易方达、广发、华夏、平安基金等多家头部公募基金频频调研各大连锁药店上市公 司，甚至有非医药的A股基金经理将十大重仓股席位几乎一半都安排在连锁药店赛道上，凸显出闭店潮强弩之 末时，基金经理已嗅到行业见底反转的机遇。 与A股基金经理策略相互呼应的是，虽然日本也在经历药店闭店潮，但今年一季度开始有全球著名的基金产品 在日本市场重仓四只连锁药店股票并大幅度获利，多个重仓中国连锁药店的A股基金经理则解释核心逻辑是挖 掘该赛道行业反转的可能性，并关注该赛道在经营场景中逐步增加慢病管理、宠物经济、保健品、药妆甚至彩 票等多元化业务带来的天花板突破机会。 闭店潮强弩之末，公募重新审视连锁药店赛道 在经历连续两年的闭店潮后，公募基金眼中的院外医药行业正迎来底部的战略性机会。 "连锁药店未来十年的需求是十分强劲的，消费支出场景可能不仅仅是用户进店买药，过去两年的关店潮会促 使市场集中度进一步提升，从而强化和增厚行业龙头的份额占有率和 ...

Market Overview - The market rebounded with the Hang Seng Index closing up 0.37% following a stabilizing meeting [1] - The Federal Reserve maintained the benchmark interest rate at 4.25%-4.50%, marking the third consecutive meeting without a change [1] - President Trump announced a significant trade agreement with a respected country, likely the UK, which may positively impact the US stock market [1][2] Trade Agreements - The trade agreement with the UK is not a traditional free trade agreement but rather a specific agreement to lower tariffs on certain goods [2] - The agreement is expected to stimulate the US stock market, despite uncertainties regarding Trump's adherence to future agreements [2] Technology Sector - The Trump administration plans to revoke AI chip restrictions from the Biden era, which faced opposition from tech companies and foreign governments [3] - This policy change is anticipated to benefit companies like NVIDIA, which saw a stock increase of over 3% [3] Geopolitical Tensions - Ongoing India-Pakistan conflict has led to significant market reactions, with the KSE-30 index in Pakistan dropping 7.2% due to economic instability [4] - India's recent trade agreement with the UK may provide some economic buffer, but ongoing military tensions could lead to capital flight [5] Pharmaceutical Sector - Following Trump's executive order to promote domestic drug production, the pharmaceutical sector experienced a significant drop but rebounded as the market adjusted to potential limitations on import tariffs [6] - The US relies heavily on imported raw materials for pharmaceuticals, with over 80% dependence, primarily from China [6] Automotive Sector - Great Wall Motors reported a 7% decline in total revenue for Q1, but April sales showed a recovery with a 5.55% year-on-year increase [9] - The company is focusing on new energy vehicles, with a notable 28.42% increase in sales for April [9][10] - The launch of new models and promotional activities are expected to drive future sales growth [10] Emerging Markets - The Chinese autonomous taxi market is projected to grow significantly, with Goldman Sachs predicting 500,000 Robotaxis by 2030 and a market size of $47 billion by 2035 [8] - Early entrants in this market, such as Pony.ai and WeRide, are expected to benefit from favorable regulatory conditions and consumer acceptance [8]

Group 1 - The core viewpoint of the article highlights the significant growth and low valuation of the Hang Seng Medical Index ETF, indicating a potential investment opportunity in the healthcare sector [3] - The Hang Seng Medical Index ETF experienced a turnover of 5.22% during the trading session, with a transaction volume of 13.05 million yuan, and a scale increase of 38.30 million yuan over the past month [3] - The ETF's shares increased by 5 million over the past two weeks, reflecting strong demand [3] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index is 24.24, which is in the 5.09% percentile over the past year, indicating that the valuation is lower than 94.91% of the time in the last year, suggesting a historical low [3] - As of May 7, 2025, the top ten weighted stocks in the Hang Seng Medical Index include WuXi AppTec, BeiGene, Innovent Biologics, and others, collectively accounting for 56.7% of the index [3] - According to Xinda Securities, the innovative drug sector is expected to show high investment value in the second quarter of 2025 due to positive industry dynamics and policy support, including expected outcomes from medical insurance negotiations and the recovery of the hospital market [3]

Investment Rating - The report rates the pharmaceutical industry as "Outperform" [1] - Sub-industry ratings include "Add" for pharmaceutical manufacturing and pharmaceutical services [1] Core Insights - The report is optimistic about innovative drugs, CXO, and strong consumer performance in Q1 2025 [5][27] - In April 2025, the pharmaceutical sector performed similarly to the market, with the SHCOMP index down 1.7% and SW Pharma Bio down 2.1%, ranking 11th among Shenwan primary industries [9][28] - The premium of the pharmaceutical sector over all A-Shares is currently at a normal level of 81.01% [18][28] Summary by Sections 1. Focus on Innovative Drugs and CXO - Key A-share stocks recommended include Jiangsu Heng Rui Medicine, Betta Pharmaceuticals, Shenzhen Salubris Pharmaceuticals, Sichuan Kelun Pharmaceutical, Remegen, Huadong Medicine, WuXi AppTec, APT Medical, and AIER EYE HOSPITAL GROUP [5][27] - H-share top picks include Wuxi Biologics Cayman, PATEO, Innovent Biologics, and Zai Lab, with beneficiaries being CSPC Pharmaceutical Group, Gushengtang, and Angelalign [27] 2. April 2025 Pharmaceutical Sector Performance - The pharmaceutical sector's performance was on par with the market, with notable sub-sectors being chemical preparations (+2.8%), pharmaceutical commerce (+1.5%), and chemical raw materials (+0.7%) [12][28] - Top gainers included Apichope Pharmaceutical (+56.2%), Qianjiang Yongan Pharmaceutical (+55.9%), and Kexing Biopharm Co., Ltd. (+55.2%), while top losers were Hainan Poly Pharm (-71.9%), Landfar Bio-Medicine Co., Ltd (-40.0%), and Jiangsu Wuzhong Industrial (-39.5%) [17][28] 3. Performance Disparities in 2024 and Q1 2025 - In 2024, the pharmaceutical sector's overall revenue fell by 1.5% YoY, and net profit decreased by 12.5% YoY, with medical consumables, chemical preparations, and blood products showing positive growth [22][28] - In Q1 2025, the sector's revenue fell by 6.1% YoY, and net profit fell by 9.7% YoY, with medical R&D outsourcing, consumables, and hospitals performing well [22][28] 4. Profitability Metrics - The gross profit margin (GPM) for the pharmaceutical sector fell by 0.5pp YoY in 2024, while the net profit margin (NPM) fell by 0.8pp YoY [24][28] - In Q1 2025, GPM decreased by 1.6pp YoY, and NPM decreased by 0.4pp YoY, with medical R&D outsourcing showing improvements in both GPM and NPM [24][28]

| 国泰君安国际(01788) | 50.00 万 | 52.01 万 | 2444.50 万 | 0.256% | | --- | --- | --- | --- | --- | | 捷利交易宝(08017) | 104.00 万 | 46.53 万 | 1960.80 万 | 3.270% | | 蒙牛乳业(02319) | 2.00 万 | 39.80 万 | 2125.20 万 | 0.540% | | 威高股份(01066) | 6.00 万 | 34.58 万 | 526.24 万 | 1.164% | | 中国东方航空股份 | 13.20 万 | 32.00 万 | 3999.60 万 | 0.773% | | (00670) | | | | | | 力鸿检验(01586) | 5.60 万 | 14.58 万 | 1353.20 万 | 24.974% | | 天鸽互动(01980) | 20.00 万 | 11.60 万 | 9012.80 万 | 7.497% | | 昊海生物科技(06826) | 4700.00 | 11.49 万 | 270.38 万 | 9.135% | | 澳优( ...

Summary of the Conference Call Industry Overview - The pharmaceutical sector is experiencing a resurgence driven by strong domestic and foreign demand, with the innovative drug segment performing particularly well. The recovery of medical insurance policies and limited impact from Sino-US trade tensions have contributed to this positive trend. Institutional holdings have notably increased [1][4][5]. Key Points and Arguments - **Innovative Drugs**: The innovative drug sector is recommended for overweight allocation due to strong demand and supply dynamics. Companies in this segment have shown better-than-expected performance, supported by favorable policy changes [1][10]. - **Medical Devices**: The electrophysiology and orthopedic consumables sectors are highlighted as areas of strong performance. Orthopedic consumables benefit from a low base and domestic substitution, while electrophysiology maintains stable growth [1][6]. - **CXO Sector**: The CXO sector has shown robust performance, with companies like Kangde Biological and LianTuo Biological reporting impressive results. The first quarter results indicate a strong growth momentum, making this sector a viable investment option [1][7]. - **Consumer Healthcare**: Overall performance in consumer healthcare is lukewarm, but leading companies like Aier Eye Hospital and JD Health have exceeded expectations, demonstrating their ability to gain market share amid a consumption downturn [1][8]. - **Upstream Supply Chain**: While overall performance in the upstream supply chain is not as strong as in innovative drugs, companies like Baipusais and Nawei Technology have shown significant competitive advantages, increasing their market share during the industry downturn [1][9]. Additional Important Insights - **Market Performance in April 2025**: The pharmaceutical sector had a lackluster performance in April, with the Shanghai Composite Index down 1.7% and the Shenwan Pharmaceutical Index down 2.1%. Notable gainers included Yipin Hong and Yong'an Pharmaceutical, both up 56% [3]. - **Investment Strategy**: The strategy suggests overweighting innovative drugs and gradually increasing allocation to reasonably valued CXO companies. Individual stock selection is recommended for consumer and upstream supply chain investments [1][10][12]. - **Monthly Portfolio Changes**: The May 2025 portfolio includes large-cap pharmaceutical stocks such as Heng Rui Pharmaceutical and BeiDa Pharmaceutical, reflecting positive changes in their fundamentals and strong R&D capabilities [2][13]. - **Rationale for Large-Cap Stocks**: The focus has shifted to larger companies due to their improved fundamentals and strong R&D capabilities, as smaller companies have already seen significant price increases [14]. - **Specific Company Recommendations**: - **Heng Rui Pharmaceutical**: Leading in R&D among traditional large enterprises, with over 100 projects in development [15]. - **Hua Dong Pharmaceutical**: Valued at approximately 16 times earnings, with a promising transition and sales growth expected [16]. - **BeiDa Pharmaceutical**: Expected to adopt more collaborative R&D approaches, making it a valuable investment at current valuations [17]. - **Xinda**: Anticipated revenue growth from 1.4 billion to 2.4 billion, with a favorable outlook due to policy improvements [18]. - **Kelong Biotechnology**: Notable performance in clinical trials, making it a strong candidate for investment [19]. - **Xinda**: Projected revenue of 40 billion in Q1, with a strong annual forecast [20]. - **Rongchang Biological**: Long-term tracking with good overseas positioning [21]. - **CXO Companies**: Notable mentions include WuXi AppTec and WuXi Biologics, recognized for their solid fundamentals [22].

Summary of Key Points Core Viewpoint - On May 2, 37 Hong Kong-listed companies conducted share buybacks, totaling 23.26 million shares and an aggregate amount of HKD 179 million [1]. Group 1: Buyback Details - The company with the highest buyback amount on May 2 was Green Bamboo Bio-B, which repurchased 1.76 million shares for HKD 39.71 million, with a maximum price of HKD 23.00 and a minimum price of HKD 21.95 [1][2]. - China Hongqiao repurchased 2.79 million shares for HKD 39.39 million, with a maximum price of HKD 14.20 and a minimum price of HKD 14.02, bringing its total buyback amount for the year to HKD 20.74 billion [1][2]. - Swire Pacific A repurchased 0.33 million shares for HKD 22.59 million, with a maximum price of HKD 68.95 and a minimum price of HKD 66.95, totaling HKD 15.26 billion for the year [1][2]. Group 2: Notable Buybacks - AIA Group conducted multiple buybacks throughout the year, with a total buyback amount of HKD 7.69 billion, including a buyback of HKD 16.07 million on May 2 [2]. - The company with the highest number of shares repurchased on May 2 was Ying Group, which bought back 7 million shares [1][2]. - Other notable companies in terms of buyback volume included China Hongqiao and Four Seasons Pharmaceutical, with repurchases of 2.79 million shares and 2.68 million shares, respectively [1][2].

Investment Rating - The report indicates a cautious outlook for the pharmaceutical industry, with a focus on recovery in 2024 after a challenging 2023 due to anti-corruption measures [6][19]. Core Insights - The pharmaceutical industry is projected to see a decline in sales revenue and net profit for 2024 compared to 2023, with total sales revenue growth at -0.46%, net profit at -6.73%, and non-recurring net profit at -11.97% [2][13]. - The fastest-growing segments in Q4 2024 are expected to be CXO, medical devices, and pharmaceutical distribution, while in Q1 2025, the growth leaders will shift to CXO, pharmacies, and pharmaceutical distribution [22]. - The report highlights a significant slowdown in growth for traditional Chinese medicine and a mixed performance across various sectors, with some showing resilience and others facing challenges [5][24]. Summary by Sector Pharmaceutical Industry - In 2024, the total revenue growth for 405 pharmaceutical companies is projected at -0.46%, with net profit declining by 6.73% [2][13]. - Q1 2025 shows a continued decline in revenue and net profit, indicating ongoing challenges [13]. Traditional Chinese Medicine - For 62 listed companies in traditional Chinese medicine, revenue and net profit are expected to decline by -3.9% and -14.6% respectively in 2024, with further declines in Q1 2025 [24][32]. Chemical Preparations - The 96 chemical preparation companies are expected to see revenue growth of 1.2% and net profit growth of 15.7% in 2024, with a slight slowdown in Q1 2025 [2][5]. Research Services - The 16 research service companies are projected to experience a revenue increase of 6.56% in 2024, despite a significant drop in net profit [2][5]. Medical Services - The 11 medical service companies are expected to face revenue growth of 1.4% in 2024, with a notable recovery in Q1 2025 [2][5]. Medical Devices - The 97 medical device companies are projected to see a slight revenue increase of 1.16% in 2024, with a decline in net profit [2][5]. Biopharmaceuticals - The 54 biopharmaceutical companies are expected to see a revenue decline of -6.9% in 2024, with a significant drop in Q1 2025 [3][5]. CXO - The 22 CXO companies are projected to experience a revenue decline of -4.14% in 2024, but a recovery is anticipated in Q1 2025 with a revenue increase of 13.1% [3][5]. Raw Materials - The 50 raw material companies are expected to see a slight revenue increase of 2.48% in 2024, with a recovery trend starting in Q1 2025 [3][5]. Pharmacies - The 7 pharmacy companies are projected to see revenue growth of 4.9% in 2024, but face challenges in Q1 2025 [2][5]. Pharmaceutical Distribution - The 22 pharmaceutical distribution companies are expected to see a slight revenue increase of 0.27% in 2024, with ongoing challenges in Q1 2025 [2][5].